Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for EndariĀ® (L-glutamine oral powder). This…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks